Study finds cyclosporine A gel effective against dry eye disease
China: A new study published in Drug Design, Development and Therapy Journal shows that participants treated with cyclosporine A gel (CyclAGel, 0.05% CsA) QD for moderate-to-severe dry eye disease (DED) clinically improved and had better statistics in inferior corneal staining score (ICSS), tear production, and symptoms.
Dry eye disease is a multifactorial ocular surface illness characterized by a lack of tear film equilibrium and accompanied by ocular symptoms. DED is caused by tear film instability and hyperosmolarity, ocular surface inflammation and injury, and neurosensory abnormalities. Cyclosporine A (CsA) is a selective immunomodulator that reduces T-cell activation and T-lymphocyte infiltration of the lacrimal glands, inhibits ocular surface epithelial cell death, and is useful in the treatment of DED. This study was carried out by Wenyan Peng and colleagues in order to confirm the effectiveness and safety of a new ophthalmic CyclAGel, 0.05% in treating patients with moderate-to-severe dry eye conditions.
The COSMO study was a multicenter, randomized, double-masked, vehicle-controlled phase III experiment. Between November 2020 and April 2021, patients with moderate-to-severe DED were enrolled at 37 hospitals in China. Eligible participants were randomly assigned to receive either CyclAGel 0.05% or vehicle eye drops once a night (QD). The primary endpoint was the proportion of patients who improved by at least one point on the ICSS at day 84. TEAEs (treatment-emergent adverse events) were documented.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.